Publication: Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series
2
Issued Date
2020-01-01
Resource Type
ISSN
16000536
01051873
01051873
Other identifier(s)
2-s2.0-85088638175
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Contact Dermatitis. (2020)
Suggested Citation
Josefin Ulriksdotter, Cecilia Svedman, Magnus Bruze, Jenny Glimsjö, Kajsa Källberg, Thanisorn Sukakul, Martin Mowitz Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series. Contact Dermatitis. (2020). doi:10.1111/cod.13649 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/58318
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series
Abstract
© 2020 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.